KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Cash from Financing Activities data on record, last reported at -$10.1 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 83.47% year-over-year to -$10.1 million; the TTM value through Dec 2025 reached -$31.5 million, up 85.11%, while the annual FY2025 figure was -$31.5 million, 85.11% up from the prior year.
  • Cash from Financing Activities reached -$10.1 million in Q4 2025 per AMRX's latest filing, down from $59.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $59.4 million in Q3 2025 and bottomed at -$100.8 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is -$35.0 million, with a median of -$36.6 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: crashed 354.87% in 2023, then surged 164.37% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$30.4 million in 2021, then grew by 26.96% to -$22.2 million in 2022, then plummeted by 354.87% to -$100.8 million in 2023, then surged by 39.3% to -$61.2 million in 2024, then surged by 83.47% to -$10.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$10.1 million in Q4 2025, $59.4 million in Q3 2025, and -$41.7 million in Q2 2025.